RESUMO
A multicentric clinical trial was done to evaluate the clinical efficacy of milbemycin oxime in the treatment of nasal mite (Pneumonyssoides caninum) infection in dogs. Milbemycin oxime was given to 70 dogs of different breeds, genders, and ages, with clinical signs associated with nasal mite infection. Twenty-five dogs had a verified infection, and 45 dogs had signs suggestive of nasal mite infection. Milbemycin oxime was given at the dosage of 0.5 to 1.0 mg/kg body weight orally once a week for three consecutive weeks. One month after initiation of treatment, 68 of the dogs had no more clinical signs associated with nasal mite infection.
Assuntos
Antibacterianos/uso terapêutico , Doenças do Cão/tratamento farmacológico , Inseticidas/uso terapêutico , Macrolídeos , Infestações por Ácaros/veterinária , Doenças Nasais/veterinária , Administração Oral , Animais , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Doenças do Cão/parasitologia , Cães , Feminino , Inseticidas/administração & dosagem , Inseticidas/efeitos adversos , Masculino , Infestações por Ácaros/tratamento farmacológico , Doenças Nasais/tratamento farmacológico , Doenças Nasais/parasitologiaRESUMO
The clinical features and the titres to Ehrlichia equi, E canis, E risticii, Rickettsia rickettsii and Borrelia afzelii in 14 Swedish dogs, in which ehrlichiosis was diagnosed on the basis of the presence of inclusions in granulocytes, are reported. Most of the dogs were moderately ill but made a rapid recovery after treatment with doxycycline. The dogs with inclusions were thrombocytopenic. Analysis of the antibody titres indicates that serology to E equi will remain the most appropriate serological test for granulocytic ehrlichiosis in Swedish dogs, until a specific test is developed for detecting the recently identified subspecies of Ehrlichia.